Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study

Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study

This phase III, randomized, placebo-controlled study conducted in three stages (6-week, randomized, placebo-controlled stage 1; 24-week, open-label stage 2; and continuous extension stage 3) assessed the long-term efficacy and safety of eltrombopag use in Chinese patients with chronic immune thrombo...

Full description

Bibliographic Details
Main Authors: Xiaofan Liu, Ming Hou, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Renchi Yang
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Platelets
Subjects:
asian continental ancestry
chinese patients
chronic immune thrombocytopenia (itp)
eltrombopag
platelet count
Online Access:http://dx.doi.org/10.1080/09537104.2020.1847267

Internet

http://dx.doi.org/10.1080/09537104.2020.1847267

Similar Items